title: Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial.
abstract: BACKGROUND
  Maintenance use of nonsteroidal anti-inflammatory drugs (NSAIDs) is often complicated by gastropathy. In non-NSAID users, eradication of Helicobacter pylori is associated with decreased mucosal inflammation, and may halt the progression to atrophy and intestinal metaplasia, but the continuous use of NSAIDs may interfere with these processes.
  
  
  OBJECTIVE
  To investigate the effect of H. pylori eradication on gastric mucosal histology during long-term NSAID use, with and without gastroprotective therapy.
  
  
  METHODS
  Patients were eligible for inclusion if they were on long-term NSAIDs and were H. pylori-positive on serologic testing. Patients were randomly assigned to either eradication or placebo. Gastritis was assessed according to the updated Sydney classification for activity, chronic inflammation, gastric glandular atrophy, intestinal metaplasia, and H. pylori density.
  
  
  RESULTS
  Biopsy specimens were available for histology of 305 patients. Of these, 48% were on chronic gastroprotective medication. Significant less active gastritis, inflammation, and H. pylori density was found in the eradication group compared with the placebo group in both corpus and antrum (P<0.001). In the corpus, less atrophy was found in the eradication group compared with the placebo group.
  
  
  CONCLUSIONS
  H. pylori eradication in patients on long-term NSAID therapy leads to healing of gastritis despite ongoing NSAID therapy.
authors.affiliation: Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands. m.deleest@vumc.nl
authors.forename: Helena T J I
authors.initials: HT
authors.lastname: De Leest
authors.forename: Kirsti S
authors.initials: KS
authors.lastname: Steen
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Bloemena
authors.forename: Willem F
authors.initials: WF
authors.lastname: Lems
authors.forename: Ernst J
authors.initials: EJ
authors.lastname: Kuipers
authors.forename: Mart A F J
authors.initials: MA
authors.lastname: Van de Laar
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: Matthijs
authors.initials: M
authors.lastname: Janssen
authors.forename: Harry H M L
authors.initials: HH
authors.lastname: Houben
authors.forename: Piet J
authors.initials: PJ
authors.lastname: Kostense
authors.forename: Maarten
authors.initials: M
authors.lastname: Boers
authors.forename: Ben A C
authors.initials: BA
authors.lastname: Dijkmans
mesh_terms: D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology; D005756:Gastritis / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole